One-Sided Sequential Stopping Boundaries for Clinical Trials: A Decision- Theoretic Approach

DOI10.2307/2531909zbMath0707.62263OpenAlexW2330412569WikidataQ52570213 ScholiaQ52570213MaRDI QIDQ3489333

Chih-Hsiang Ho, Donald A. Berry

Publication date: 1988

Published in: Biometrics (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.2307/2531909

zbMATH Keywords

dynamic programmingoptimal stoppingclinical trialssubjective probabilityBayesian inferencebackward inductioncost-benefit analysisgroup sequential analysispredictive densitydrug developmentinterim analysispharmaceutical decisions

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Related Items (14)

Bayesian designs and the control of frequentist characteristics: A practical solution ⋮ Methodology and application of adaptive and sequential approaches in contemporary clinical trials ⋮ Posterior alternatives with informative early stopping ⋮ A Review of Modern Computational Algorithms for Bayesian Optimal Design ⋮ Generalization of a lemma of kiefer and weiss for the case of sequentially planned decision problems with more than two hypotheses ⋮ Analysis of local decisions using hierarchical modeling, applied to home radon measurement and remediation. (With comments and a rejoinder). ⋮ Decision‐theoretic designs for a series of trials with correlated treatment effects using the Sarmanov multivariate beta‐binomial distribution ⋮ Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes ⋮ A Bayesian Group Sequential Approach for Multiple Endpoints ⋮ Self-Designing Two-Stage Trials to Minimize Expected Costs ⋮ Decision-Theoretic Designs for Phase II Clinical Trials Allowing for Competing Studies ⋮ Sequential Testing to Guarantee the Necessary Sample Size in Clinical Trials ⋮ Bayesian Uncertainty Directed Trial Designs ⋮ Experimental design for drug development: a bayesian approach

This page was built for publication: One-Sided Sequential Stopping Boundaries for Clinical Trials: A Decision- Theoretic Approach